FGFR2 Mutation Analysis for TKI Resistance Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tyrosine kinase inhibitors (TKIs) face challenges with long-term efficacy due to primary and secondary resistance in patients, particularly in cancers with amplified or mutationally activated FGFR2 kinase, where specific resistance profiles and mutation variants confer resistance to FGFR inhibitors, limiting the effectiveness of treatments.
Innovation Solution
A method involving the analysis of FGFR2 kinase mutation variants such as M536I, M538I, I548V, N550H, N550K, N550S, V565I, E566G, L618M, E719G, and Y770IfsX14 in tumor samples to determine drug resistance or sensitivity, guiding the administration of specific tyrosine kinase inhibitors like ponatinib, BGJ398, AZD4547, and DCC2036 for personalized treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tyrosine kinase inhibitors are used to treat FGFR2-driven cancers, then initial treatment efficacy is improved, but long-term efficacy deteriorates due to drug resistance
Solution Approach 1:
The patent performs preliminary genetic analysis of FGFR2 mutations before initiating TKI treatment. By identifying specific mutation variants (such as Y770C, Y770S, Y770N) that predispose patients to resistance, the system selects appropriate TKI agents in advance, preventing resistance development before it occurs and thereby extending long-term treatment efficacy.
Solution Approach 2:
The patent changes the selection parameter from empirical drug choice to genetically-guided drug selection. By analyzing FGFR2 mutation status and matching patients with TKIs based on their specific mutation profile, the system optimizes treatment parameters to overcome resistance mechanisms, thereby maintaining reliable efficacy over extended treatment periods.
2Ease of operation
If a single TKI agent is used for treatment, then treatment simplicity is improved, but adaptability to different mutation profiles deteriorates
Solution Approach 1:
The patent applies local quality by tailoring TKI selection to each patient's specific FGFR2 mutation profile. Different TKI agents are matched to different mutation variants (e.g., specific TKIs for Y770C, Y770S, or Y770N mutations), ensuring that the treatment is locally optimized for each genetic context while maintaining an overall simple genetic testing-based decision framework.
Solution Approach 2:
The patent changes the treatment parameter from a one-size-fits-all approach to a mutation-stratified approach. By introducing genetic profiling as a selection criterion, the system adapts TKI agent choice to match specific FGFR2 mutation variants, thereby achieving versatility across different mutation profiles while preserving ease of operation through standardized genetic testing protocols.
3Duration of action of stationary object
If TKI treatment is continued long-term, then treatment coverage is improved, but development of resistance mutations increases
Solution Approach 1:
The patent applies preliminary anti-action by identifying and preventing resistance mutations before they develop. Through baseline genetic analysis of FGFR2, the system selects TKI agents that are preemptively effective against potential resistance mechanisms, thereby allowing long-term treatment continuation without the emergence of harmful resistance mutations.
Solution Approach 2:
The patent implements feedback by using genetic information to guide TKI selection, creating a closed-loop system where mutation status directly informs treatment choice. This feedback mechanism allows the system to adapt to the specific genetic landscape of each patient, enabling sustained treatment efficacy over time while minimizing the development of resistance through genetically-informed agent selection.
Data Source
AI summary
This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, using these molecules and fragments thereof, and kits for employing these methods and compositions.